InSphero AG has acquired PhenoVista Biosciences, Inc., a San Diego-based provider of high-content imaging and phenotypic assay services. The deal combines PhenoVista’s expertise in imaging-based assay development and cell painting with InSphero’s leadership in scalable 3D microtissue models and microphysiological systems. Financial terms were not disclosed.
PhenoVista Biosciences is a contract research organization (CRO) that develops and executes disease-relevant, cell-based assays for biopharmaceutical clients of all stages and sizes using advanced cell models combined with high-content imaging and sophisticated data-analysis capabilities.
Based in Switzerland, InSphero AG is a global leader in advanced 3D in vitro models and services for drug safety and efficacy testing, with a focus on scalable spheroid-based microtissues and predictive human-relevant models. The combined platform strengthens capabilities across oncology, fibrosis, neuroscience and safety assessment.
The acquisition marks InSphero’s second deal in 2026 following the DOPPL SA transaction and significantly expands its presence and operational capabilities in the United States. PhenoVista will integrate into InSphero while maintaining its strong scientific team and customer focus under the broader global infrastructure.
According to data captured in the LevinPro HC database, this transaction represents the 40th Life Sciences R&D acquisition of the year, as well as the 15th in the CRO subsector. There were 84 Life Sciences R&D deals announced in 2025, including 18 CRO deals. In 2024, there were 92 Life Sciences R&D and 35 CRO transactions announced.
